Compugen Earnings Conference Call (Q2 2012) Today's Calls 
Visit the TF Network Sites
Visit the TF Network Sites
· Corporate IR Center
· Institutional Investor Center
· Individual Investor Center
Download Plug-In
Real Player 8 Basic
Windows Media Player
Other Conference Calls
Other Aug 7 Calls
Today's Calls
Call Details
Compugen Earnings Conference Call (Q2 2012)
Scheduled to start Tue, Aug 7, 2012, 10:00 am Eastern

-- this event is ongoing now--
Listen to the ongoing live event audio stream

About Compugen Ltd (NasdaqCM:CGEN)Other Calls 
Compugen Ltd., an early stage drug and diagnostic discovery company, engages in the research, development, and commercialization of therapeutic peptides and proteins for cancer, cardiovascular, and immune-related diseases in the United States and Europe. The company’s therapeutic peptide and protein related platforms include GPCR Therapeutic Peptide Ligands, Disease-Associated Conformation Blockers, Viral Peptides, and Splice Variant based Therapeutic Proteins; monoclonal antibody related platforms comprise Monoclonal Antibody Targets; and other therapeutic and diagnostic platforms consist of Nucleic-Acid Disease Markers, Protein Disease Markers, Nucleic-Acid Preclinical Toxicity Markers, Non-SNP Drug Response Markers, and New Indications. Its therapeutic peptide and protein product candidates comprise CGEN-855, a peptide agonist of the FPRL1 GPCR receptor; CGEN-856 and CGEN-857, which are MAS GPCR peptide agonists; CGEN-25007, an antagonist of the gp96 protein; CGEN-25008, a peptide antagonist; CGEN-25009, a peptide of the LGR7 receptor; CGEN-25017, a peptide antagonist; and CGEN-15001, a protein for the treatment of autoimmune disorders. The company also offers monoclonal antibody target product candidates, including CGEN-671, a drug for multiple epithelial tumors. In addition, it provides various therapeutic and diagnostic product candidates, such as CGEN-40001, a genetic biomarker for predisposition to type-2 diabetes; CGEN-226, a biomarker for early detection of preeclampsia; CGEN-327, a biomarker for ovarian cancer; and CGEN-50001, a small molecule drug for CNS related indications. Compugen has collaboration agreements with Pfizer and Bayer Schering Pharma AG. The company was founded in 1993 and is based in Tel Aviv, Israel.

More Info: Quote | Chart | News | Profile | Reports | Research | Msgs | Financials

Copyright © 2012 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Copyright © 2012 FirstCall Events. Historical chart data provided by Commodity Systems, Inc. (CSI). Company profile information presented on this page is Copyright Capital IQ. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.